Zenas BioPharma, Inc. ZBIO 深 滬
等待開盤 05-20 09:30:00 美东时间
17.84
+0.930
+5.50%
華盛通- 最 高18.255
- 今 開17.92
- 成交量 65.91万股
- 最 低 17.02
- 昨 收 16.91
- 總市值 11.26亿
- 52周最高 44.60
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 8.91
- 委 比 -57.97%
- 總股本 6313.34万
- 歷史最高 44.60
- 量 比 1.05
- 振 幅 7.30%
- 歷史最低 5.83
- 每 手 1
- 風險率 8.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF Inhibitor
The ZB021 Phase 1 trial is supported by robust preclinical data demonstrating a desirable pharmacology and toxicology profile. In addition to potent inhibition of IL-17AA/AF signaling, and anti-inflammatory activity
05-13 18:52
Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.17) by 24.79 percent. This is a 82.5 percent decrease over losses of $(0.80) per share from
05-13 18:32
Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
Zenas BioPharma shares are trading lower after the company announced it commenced an underwritten public offering of convertible senior notes and shares of its common stock.
Zenas BioPharma shares are trading lower after the company announced it commenc...
03-27 04:35
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
03-17 18:54
Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(4.54) per share. This is a 260.32 percent decrease over losses of $(1.26) per share from the same period last year.
03-16 19:22
